Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Tumor Lysis Syndrome 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Hyperuricemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Urate Oxidase × Clear all
NCT00057811 2014-09-19

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Children's Oncology Group

Phase 2 Completed
97 enrolled 13 charts
LymphoidSarcoma

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡